CHICAGO, Sept. 4, 2009 (GLOBE NEWSWIRE) -- The Female Health Company (Nasdaq:FHCO), which manufactures and markets the FC1 and FC2 Female Condom(r), today announced that the Company's CEO, O.B. Parrish, and its CFO, Donna Felch, are scheduled to make a presentation at Rodman & Renshaw's 11th Annual Healthcare Conference at 12:05 p.m. on Thursday, September 10, 2009.
The Conference will be held September 9-11, 2009 at the New York Palace Hotel in New York City. Additional information on the Conference is available on the Internet at http://www.rodmanandrenshaw.com/conferences?id=30 .
The Female Health Company's presentation will be webcast "live" on the Internet at http://www.wsw.com/webcast/rrshq15/fhco .
About Rodman & Renshaw
Rodman & Renshaw is a full-service investment banking firm that is dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. The firm also provides research, sales and trading services to institutional investor clients that focus on such companies.
Through its life sciences investment banking team, Rodman & Renshaw provides a broad range of investment banking services to biotechnology, specialty pharmaceutical, medical device and other companies operating in the life science space. The team consists of seasoned professionals, many of whom have PhDs or other advanced medical or scientific degrees. Their experience and expertise enable the firm to deliver the specialized advice and differentiated services its clients demand.
Additional information on Rodman & Renshaw is available on the Internet at www.rodmanandrenshaw.com .
About The Female Health Company
The Female Health Company (FHC), headquartered in Chicago, IL, is the maker of the FC Female Condom (FC1 and FC2), a revolutionary option offering women dual protection against both sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company in February 1996 with the purchase of Chartex Resources Ltd., the holder of exclusive worldwide rights to FC1. The Company holds exclusive product and technology patents for FC1 in the United States, Australia, Brazil, Canada, France, Germany, Italy, Spain, the United Kingdom, the People's Republic of China, South Korea and Japan. FC2 patents have been granted in Australia, Canada and South Africa and are pending in various other countries. FHC is the sole manufacturer and marketer of the FC1 and FC2 female condoms in the world. The Female Health Company and its partners currently market the Female Condom under FC Female Condom(r), FC2 Female Condom(r), Reality(r), Femidom(r), Femy(r), and Care(r).
"Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995:
The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's web site at http://www.femalehealth.com and http://www.femalecondom.org.
If you would like to be added to an e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com